Physician profile
Malissa Wall
NPI 1275820235
$1,411.50
in general payments reported to CMS, 2019-2025
17 companies · $371 in 2025
The $371 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $67.35 · 2022: $103 · 2023: $312 · 2024: $286 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $489.10 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $182.00 | 2024-2025 | Qelbree |
| Glaxosmithkline, LLC. | $150.14 | 2019-2024 | Bexsero |
| Pfizer INC. | $120.08 | 2019-2023 | |
| Sanofi Pasteur INC. | $116.47 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $76.40 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ironshore Pharmaceuticals INC. | $42.90 | 2019 | |
| Sobi, INC | $41.96 | 2019 | |
| Genentech USA, INC. | $39.69 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.26 | 2024 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $25.38 | 2025 | Voxzogo 1.2mg |
| Tris Pharma INC | $24.44 | 2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $18.29 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $17.76 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.11 | 2025 | Zoryve |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.52 | 2019 | |
| Glenmark Therapeutics INC. | $4.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malissa Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.